PharmaTelevision - BIO: Growth of Australia in biotechnology sector and the similarities with the US

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BIO: Growth of Australia in biotechnology sector and the similarities with the US

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to James C Greenwood, President and CEO of Biotechnology Industry Organisation (BIO). They discuss:

• Growth of Australia in biotechnology sector

• Similarities between Australia and US in biotechnology industry

• Cooperation between BIO and AusBiotech

• What are the effects of healthcare reforms on investments in biotech sector in US?

• Future plans

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Growth of Australia in biotechnology sector

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech in Melbourne. On this show I have James C. Greenwood, who is President and CEO of BIO based in the US, welcome to the show.

James C. Greenwood:

Thank you, thanks for having me.

Fintan Walton:

James C. Greenwood , you are here in Australia, what do you think of Australia?

James C. Greenwood:

I think Australia has made incredible strides and they have very clearly articulated ambitions when it comes to biotechnology you know just yesterday the premier of Victoria where we are sitting came out what I think what is their third biotech plan, there are not very many states in the United States that have biotechnology plans, so to see that in a place like Victoria is really quite impressive. And what they've done is amazing and particularly if you think in terms of the investment in dollars per capita, this is a country of 22 million people, it is a state Victoria is a state of 5 million people and yet they have been invested in huge make huge investments I am talking about half a billion dollars in a new cancer centre hospitals at the La Trobe University where I was yesterday the AgriBioscience commitment that they've made is astonishing. So you have a government here that understands both the need for a generally favorable business climate and then specifically understands the potentiality in terms of not only economic growth, but in terms of quality of life for their citizens, Australia I think very much aggressive.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

James C Greenwood

President and CEO

James C. Greenwood is President and CEO of the Biotechnology Industry Organisation in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Since his appointment in January of 2005, he has markedly enhanced the trade association's capacity " increasing both its staff and budget by nearly fifty percent. BIO is now a world class advocacy organization playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally. Mr. James C. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment. From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's vast jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies. Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992). Mr. James C. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Biotechnology Industry Organisation

Biotechnology Industry Organisation (BIO) is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals.